Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors

Everolimus, an oral mammalian target of rapamycin(mTOR) inhibitor, which acts upstream of the phosphoinositide 3-kinase/protein kinase B(PI3K/AKT) signaling pathway to downregulate cellular metabolism, growth, proliferation, and angiogenesis, has been shown to significantly prolong the progression-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Wenhao, Zhou, Dongkai, Zhu, Lijun, Song, Wei, Wang, Weilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299392/
https://www.ncbi.nlm.nih.gov/pubmed/30588264
http://dx.doi.org/10.7150/jca.25908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299392/
https://www.ncbi.nlm.nih.gov/pubmed/30588264
http://dx.doi.org/10.7150/jca.25908

Ejemplares similares